Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen

•HIV-DNA changes over 96 weeks were similar for DTG + 1 RTI and E/C/F/TAF.•Plasma HIV-RNA changes over 96 weeks were similar in the two treatment arms.•A positive correlation was found between baseline HIV-DNA and HIV-DNA levels at W96.•No correlations were found between HIV-DNA and immunological pa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of antimicrobial agents 2023-05, Vol.61 (5), p.106771-106771, Article 106771
Hauptverfasser: Scutari, Rossana, Galli, Laura, Alteri, Claudia, Poli, Andrea, Piermatteo, Lorenzo, Bigoloni, Alba, Perno, Carlo Federico, Lazzarin, Adriano, Ceccherini-Silberstein, Francesca, Castagna, Antonella, Santoro, Maria Mercedes, Gianotti, Nicola
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 106771
container_issue 5
container_start_page 106771
container_title International journal of antimicrobial agents
container_volume 61
creator Scutari, Rossana
Galli, Laura
Alteri, Claudia
Poli, Andrea
Piermatteo, Lorenzo
Bigoloni, Alba
Perno, Carlo Federico
Lazzarin, Adriano
Ceccherini-Silberstein, Francesca
Castagna, Antonella
Santoro, Maria Mercedes
Gianotti, Nicola
description •HIV-DNA changes over 96 weeks were similar for DTG + 1 RTI and E/C/F/TAF.•Plasma HIV-RNA changes over 96 weeks were similar in the two treatment arms.•A positive correlation was found between baseline HIV-DNA and HIV-DNA levels at W96.•No correlations were found between HIV-DNA and immunological parameters over time.•No correlations were generally found between viremia and immunological parameters. To investigate HIV-DNA and residual viremia (RV) levels over 96 weeks (W96) in virologically-suppressed HIV-1-infected individuals enrolled in the Be-OnE Study. Individuals were randomised to continue a two-drug regimen with dolutegravir (DTG) plus one reverse transcriptase inhibitor (RTI) or to switch to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (E/C/F/TAF). Total HIV-DNA and RV were evaluated at baseline, W48 and W96 using droplet digital polymerase chain reaction (ddPCR) technique. Potential relationships between viro-immunological parameters and between/within arms were also assessed. Median (interquartile range [IQR]) HIV-DNA was 2247 (767-4268), 1587 (556-3543) and 1076 (512-2345) copies/106 CD4+T-cells at baseline, W48 and at W96, respectively; RV was 3 (1-5), 4 (1-9) and 2 (2-4) copies/mL, respectively, with no significant differences between arms. A significant reduction in HIV-DNA and RV from baseline to W96 was observed in the E/C/F/TAF arm (HIV-DNA: -285 [-2257; -45], P=0.010; RV: -1 [-3;0], P=0.007). In the DTG + 1 RTI arm, HIV-DNA and RV levels remained stable (HIV-DNA: -549 [-2269;+307], P=0.182; RV: -1 [-3;+1], P=0.280). For both HIV-DNA and RV, there were no significant changes over time between the arms. A positive correlation was found between baseline HIV-DNA and HIV-DNA at W96 (E/C/F/TAF: Spearman correlation coefficient (rs)=0.726, P=0.0004; DTG + 1 RTI: rs=0.589, P=0.010). In general, no significant correlations were found between HIV-DNA, RV and immunological parameters over time. In virologically-suppressed individuals, there was a small reduction in HIV-DNA and HIV-RNA levels from baseline to W96 in individuals who switched to the E/C/F/TAF arm compared with those who remained on DTG + 1 RTI. However, there were no significant differences between the two arms in the changes in HIV-DNA and HIV-RNA over time.
doi_str_mv 10.1016/j.ijantimicag.2023.106771
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2783496065</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924857923000560</els_id><sourcerecordid>2783496065</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-4c7412118cc793df2e64effadffe1f36d0f3043b5def3afd79065bef294aa9083</originalsourceid><addsrcrecordid>eNqNkUGP1SAUhRujcZ6jf8Hgzk2fUNpSlpPn6Ewy0Y26JRQurzxbGIH2xZ_nP5NOR-PSDYR7zuHc5CuKNwTvCSbtu9PenqRLdrJKHvcVrmiet4yRJ8WOdKwqGSf0abHDvKrLrmH8ongR4wlj0tC6eV5c0LZjuMZ0V_y6XuQ4y2S9Q96gm9tv5ftPV0g6jQJEq2c5osUGmKxEIywwRpSG4OfjgM4A3xFvkXUPMesMqAQ6v7VdHpIRnQePlM-ruhmQROnsSx3mI_IBxbNNakDJr_MhAGyKdQmOQUZAMYV1jfWMBkJWBtvb5EPZZ3nd72gncC-LZyZXwavH-7L4-uH6y-GmvPv88fZwdVcqylgqa8VqUhHSKcU41aaCtgZjpDYGiKGtxobimvaNBkOl0YzjtunBVLyWkuOOXhZvt3_vg_8xQ0xislHBOEoHfo6iYh2teZtT2co3qwo-xgBG3Ac7yfBTECxWguIk_iEoVoJiI5izrx9r5n4C_Tf5B1k2HDZDZgGLhSCisuAU6IxJJaG9_Y-a3-ButxI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2783496065</pqid></control><display><type>article</type><title>Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Scutari, Rossana ; Galli, Laura ; Alteri, Claudia ; Poli, Andrea ; Piermatteo, Lorenzo ; Bigoloni, Alba ; Perno, Carlo Federico ; Lazzarin, Adriano ; Ceccherini-Silberstein, Francesca ; Castagna, Antonella ; Santoro, Maria Mercedes ; Gianotti, Nicola</creator><creatorcontrib>Scutari, Rossana ; Galli, Laura ; Alteri, Claudia ; Poli, Andrea ; Piermatteo, Lorenzo ; Bigoloni, Alba ; Perno, Carlo Federico ; Lazzarin, Adriano ; Ceccherini-Silberstein, Francesca ; Castagna, Antonella ; Santoro, Maria Mercedes ; Gianotti, Nicola</creatorcontrib><description>•HIV-DNA changes over 96 weeks were similar for DTG + 1 RTI and E/C/F/TAF.•Plasma HIV-RNA changes over 96 weeks were similar in the two treatment arms.•A positive correlation was found between baseline HIV-DNA and HIV-DNA levels at W96.•No correlations were found between HIV-DNA and immunological parameters over time.•No correlations were generally found between viremia and immunological parameters. To investigate HIV-DNA and residual viremia (RV) levels over 96 weeks (W96) in virologically-suppressed HIV-1-infected individuals enrolled in the Be-OnE Study. Individuals were randomised to continue a two-drug regimen with dolutegravir (DTG) plus one reverse transcriptase inhibitor (RTI) or to switch to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (E/C/F/TAF). Total HIV-DNA and RV were evaluated at baseline, W48 and W96 using droplet digital polymerase chain reaction (ddPCR) technique. Potential relationships between viro-immunological parameters and between/within arms were also assessed. Median (interquartile range [IQR]) HIV-DNA was 2247 (767-4268), 1587 (556-3543) and 1076 (512-2345) copies/106 CD4+T-cells at baseline, W48 and at W96, respectively; RV was 3 (1-5), 4 (1-9) and 2 (2-4) copies/mL, respectively, with no significant differences between arms. A significant reduction in HIV-DNA and RV from baseline to W96 was observed in the E/C/F/TAF arm (HIV-DNA: -285 [-2257; -45], P=0.010; RV: -1 [-3;0], P=0.007). In the DTG + 1 RTI arm, HIV-DNA and RV levels remained stable (HIV-DNA: -549 [-2269;+307], P=0.182; RV: -1 [-3;+1], P=0.280). For both HIV-DNA and RV, there were no significant changes over time between the arms. A positive correlation was found between baseline HIV-DNA and HIV-DNA at W96 (E/C/F/TAF: Spearman correlation coefficient (rs)=0.726, P=0.0004; DTG + 1 RTI: rs=0.589, P=0.010). In general, no significant correlations were found between HIV-DNA, RV and immunological parameters over time. In virologically-suppressed individuals, there was a small reduction in HIV-DNA and HIV-RNA levels from baseline to W96 in individuals who switched to the E/C/F/TAF arm compared with those who remained on DTG + 1 RTI. However, there were no significant differences between the two arms in the changes in HIV-DNA and HIV-RNA over time.</description><identifier>ISSN: 0924-8579</identifier><identifier>EISSN: 1872-7913</identifier><identifier>DOI: 10.1016/j.ijantimicag.2023.106771</identifier><identifier>PMID: 36870403</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adenine - therapeutic use ; Anti-HIV Agents - pharmacology ; Anti-HIV Agents - therapeutic use ; Droplet digital PCR ; Dual-regimen ; Emtricitabine - therapeutic use ; HIV Infections - drug therapy ; HIV reservoir ; Humans ; Integrases ; Residual viremia ; Reverse Transcriptase Inhibitors - therapeutic use ; RNA - therapeutic use ; Single-tablet regimen ; Tenofovir - therapeutic use ; Total HIV-DNA ; Viremia - drug therapy</subject><ispartof>International journal of antimicrobial agents, 2023-05, Vol.61 (5), p.106771-106771, Article 106771</ispartof><rights>2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy</rights><rights>Copyright © 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-4c7412118cc793df2e64effadffe1f36d0f3043b5def3afd79065bef294aa9083</citedby><cites>FETCH-LOGICAL-c377t-4c7412118cc793df2e64effadffe1f36d0f3043b5def3afd79065bef294aa9083</cites><orcidid>0000-0001-8046-0290 ; 0000-0002-6228-1114 ; 0000-0002-7182-5080</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijantimicag.2023.106771$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36870403$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scutari, Rossana</creatorcontrib><creatorcontrib>Galli, Laura</creatorcontrib><creatorcontrib>Alteri, Claudia</creatorcontrib><creatorcontrib>Poli, Andrea</creatorcontrib><creatorcontrib>Piermatteo, Lorenzo</creatorcontrib><creatorcontrib>Bigoloni, Alba</creatorcontrib><creatorcontrib>Perno, Carlo Federico</creatorcontrib><creatorcontrib>Lazzarin, Adriano</creatorcontrib><creatorcontrib>Ceccherini-Silberstein, Francesca</creatorcontrib><creatorcontrib>Castagna, Antonella</creatorcontrib><creatorcontrib>Santoro, Maria Mercedes</creatorcontrib><creatorcontrib>Gianotti, Nicola</creatorcontrib><title>Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen</title><title>International journal of antimicrobial agents</title><addtitle>Int J Antimicrob Agents</addtitle><description>•HIV-DNA changes over 96 weeks were similar for DTG + 1 RTI and E/C/F/TAF.•Plasma HIV-RNA changes over 96 weeks were similar in the two treatment arms.•A positive correlation was found between baseline HIV-DNA and HIV-DNA levels at W96.•No correlations were found between HIV-DNA and immunological parameters over time.•No correlations were generally found between viremia and immunological parameters. To investigate HIV-DNA and residual viremia (RV) levels over 96 weeks (W96) in virologically-suppressed HIV-1-infected individuals enrolled in the Be-OnE Study. Individuals were randomised to continue a two-drug regimen with dolutegravir (DTG) plus one reverse transcriptase inhibitor (RTI) or to switch to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (E/C/F/TAF). Total HIV-DNA and RV were evaluated at baseline, W48 and W96 using droplet digital polymerase chain reaction (ddPCR) technique. Potential relationships between viro-immunological parameters and between/within arms were also assessed. Median (interquartile range [IQR]) HIV-DNA was 2247 (767-4268), 1587 (556-3543) and 1076 (512-2345) copies/106 CD4+T-cells at baseline, W48 and at W96, respectively; RV was 3 (1-5), 4 (1-9) and 2 (2-4) copies/mL, respectively, with no significant differences between arms. A significant reduction in HIV-DNA and RV from baseline to W96 was observed in the E/C/F/TAF arm (HIV-DNA: -285 [-2257; -45], P=0.010; RV: -1 [-3;0], P=0.007). In the DTG + 1 RTI arm, HIV-DNA and RV levels remained stable (HIV-DNA: -549 [-2269;+307], P=0.182; RV: -1 [-3;+1], P=0.280). For both HIV-DNA and RV, there were no significant changes over time between the arms. A positive correlation was found between baseline HIV-DNA and HIV-DNA at W96 (E/C/F/TAF: Spearman correlation coefficient (rs)=0.726, P=0.0004; DTG + 1 RTI: rs=0.589, P=0.010). In general, no significant correlations were found between HIV-DNA, RV and immunological parameters over time. In virologically-suppressed individuals, there was a small reduction in HIV-DNA and HIV-RNA levels from baseline to W96 in individuals who switched to the E/C/F/TAF arm compared with those who remained on DTG + 1 RTI. However, there were no significant differences between the two arms in the changes in HIV-DNA and HIV-RNA over time.</description><subject>Adenine - therapeutic use</subject><subject>Anti-HIV Agents - pharmacology</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Droplet digital PCR</subject><subject>Dual-regimen</subject><subject>Emtricitabine - therapeutic use</subject><subject>HIV Infections - drug therapy</subject><subject>HIV reservoir</subject><subject>Humans</subject><subject>Integrases</subject><subject>Residual viremia</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>RNA - therapeutic use</subject><subject>Single-tablet regimen</subject><subject>Tenofovir - therapeutic use</subject><subject>Total HIV-DNA</subject><subject>Viremia - drug therapy</subject><issn>0924-8579</issn><issn>1872-7913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUGP1SAUhRujcZ6jf8Hgzk2fUNpSlpPn6Ewy0Y26JRQurzxbGIH2xZ_nP5NOR-PSDYR7zuHc5CuKNwTvCSbtu9PenqRLdrJKHvcVrmiet4yRJ8WOdKwqGSf0abHDvKrLrmH8ongR4wlj0tC6eV5c0LZjuMZ0V_y6XuQ4y2S9Q96gm9tv5ftPV0g6jQJEq2c5osUGmKxEIywwRpSG4OfjgM4A3xFvkXUPMesMqAQ6v7VdHpIRnQePlM-ruhmQROnsSx3mI_IBxbNNakDJr_MhAGyKdQmOQUZAMYV1jfWMBkJWBtvb5EPZZ3nd72gncC-LZyZXwavH-7L4-uH6y-GmvPv88fZwdVcqylgqa8VqUhHSKcU41aaCtgZjpDYGiKGtxobimvaNBkOl0YzjtunBVLyWkuOOXhZvt3_vg_8xQ0xislHBOEoHfo6iYh2teZtT2co3qwo-xgBG3Ac7yfBTECxWguIk_iEoVoJiI5izrx9r5n4C_Tf5B1k2HDZDZgGLhSCisuAU6IxJJaG9_Y-a3-ButxI</recordid><startdate>202305</startdate><enddate>202305</enddate><creator>Scutari, Rossana</creator><creator>Galli, Laura</creator><creator>Alteri, Claudia</creator><creator>Poli, Andrea</creator><creator>Piermatteo, Lorenzo</creator><creator>Bigoloni, Alba</creator><creator>Perno, Carlo Federico</creator><creator>Lazzarin, Adriano</creator><creator>Ceccherini-Silberstein, Francesca</creator><creator>Castagna, Antonella</creator><creator>Santoro, Maria Mercedes</creator><creator>Gianotti, Nicola</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8046-0290</orcidid><orcidid>https://orcid.org/0000-0002-6228-1114</orcidid><orcidid>https://orcid.org/0000-0002-7182-5080</orcidid></search><sort><creationdate>202305</creationdate><title>Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen</title><author>Scutari, Rossana ; Galli, Laura ; Alteri, Claudia ; Poli, Andrea ; Piermatteo, Lorenzo ; Bigoloni, Alba ; Perno, Carlo Federico ; Lazzarin, Adriano ; Ceccherini-Silberstein, Francesca ; Castagna, Antonella ; Santoro, Maria Mercedes ; Gianotti, Nicola</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-4c7412118cc793df2e64effadffe1f36d0f3043b5def3afd79065bef294aa9083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adenine - therapeutic use</topic><topic>Anti-HIV Agents - pharmacology</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Droplet digital PCR</topic><topic>Dual-regimen</topic><topic>Emtricitabine - therapeutic use</topic><topic>HIV Infections - drug therapy</topic><topic>HIV reservoir</topic><topic>Humans</topic><topic>Integrases</topic><topic>Residual viremia</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>RNA - therapeutic use</topic><topic>Single-tablet regimen</topic><topic>Tenofovir - therapeutic use</topic><topic>Total HIV-DNA</topic><topic>Viremia - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scutari, Rossana</creatorcontrib><creatorcontrib>Galli, Laura</creatorcontrib><creatorcontrib>Alteri, Claudia</creatorcontrib><creatorcontrib>Poli, Andrea</creatorcontrib><creatorcontrib>Piermatteo, Lorenzo</creatorcontrib><creatorcontrib>Bigoloni, Alba</creatorcontrib><creatorcontrib>Perno, Carlo Federico</creatorcontrib><creatorcontrib>Lazzarin, Adriano</creatorcontrib><creatorcontrib>Ceccherini-Silberstein, Francesca</creatorcontrib><creatorcontrib>Castagna, Antonella</creatorcontrib><creatorcontrib>Santoro, Maria Mercedes</creatorcontrib><creatorcontrib>Gianotti, Nicola</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scutari, Rossana</au><au>Galli, Laura</au><au>Alteri, Claudia</au><au>Poli, Andrea</au><au>Piermatteo, Lorenzo</au><au>Bigoloni, Alba</au><au>Perno, Carlo Federico</au><au>Lazzarin, Adriano</au><au>Ceccherini-Silberstein, Francesca</au><au>Castagna, Antonella</au><au>Santoro, Maria Mercedes</au><au>Gianotti, Nicola</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen</atitle><jtitle>International journal of antimicrobial agents</jtitle><addtitle>Int J Antimicrob Agents</addtitle><date>2023-05</date><risdate>2023</risdate><volume>61</volume><issue>5</issue><spage>106771</spage><epage>106771</epage><pages>106771-106771</pages><artnum>106771</artnum><issn>0924-8579</issn><eissn>1872-7913</eissn><abstract>•HIV-DNA changes over 96 weeks were similar for DTG + 1 RTI and E/C/F/TAF.•Plasma HIV-RNA changes over 96 weeks were similar in the two treatment arms.•A positive correlation was found between baseline HIV-DNA and HIV-DNA levels at W96.•No correlations were found between HIV-DNA and immunological parameters over time.•No correlations were generally found between viremia and immunological parameters. To investigate HIV-DNA and residual viremia (RV) levels over 96 weeks (W96) in virologically-suppressed HIV-1-infected individuals enrolled in the Be-OnE Study. Individuals were randomised to continue a two-drug regimen with dolutegravir (DTG) plus one reverse transcriptase inhibitor (RTI) or to switch to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (E/C/F/TAF). Total HIV-DNA and RV were evaluated at baseline, W48 and W96 using droplet digital polymerase chain reaction (ddPCR) technique. Potential relationships between viro-immunological parameters and between/within arms were also assessed. Median (interquartile range [IQR]) HIV-DNA was 2247 (767-4268), 1587 (556-3543) and 1076 (512-2345) copies/106 CD4+T-cells at baseline, W48 and at W96, respectively; RV was 3 (1-5), 4 (1-9) and 2 (2-4) copies/mL, respectively, with no significant differences between arms. A significant reduction in HIV-DNA and RV from baseline to W96 was observed in the E/C/F/TAF arm (HIV-DNA: -285 [-2257; -45], P=0.010; RV: -1 [-3;0], P=0.007). In the DTG + 1 RTI arm, HIV-DNA and RV levels remained stable (HIV-DNA: -549 [-2269;+307], P=0.182; RV: -1 [-3;+1], P=0.280). For both HIV-DNA and RV, there were no significant changes over time between the arms. A positive correlation was found between baseline HIV-DNA and HIV-DNA at W96 (E/C/F/TAF: Spearman correlation coefficient (rs)=0.726, P=0.0004; DTG + 1 RTI: rs=0.589, P=0.010). In general, no significant correlations were found between HIV-DNA, RV and immunological parameters over time. In virologically-suppressed individuals, there was a small reduction in HIV-DNA and HIV-RNA levels from baseline to W96 in individuals who switched to the E/C/F/TAF arm compared with those who remained on DTG + 1 RTI. However, there were no significant differences between the two arms in the changes in HIV-DNA and HIV-RNA over time.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>36870403</pmid><doi>10.1016/j.ijantimicag.2023.106771</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-8046-0290</orcidid><orcidid>https://orcid.org/0000-0002-6228-1114</orcidid><orcidid>https://orcid.org/0000-0002-7182-5080</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0924-8579
ispartof International journal of antimicrobial agents, 2023-05, Vol.61 (5), p.106771-106771, Article 106771
issn 0924-8579
1872-7913
language eng
recordid cdi_proquest_miscellaneous_2783496065
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Adenine - therapeutic use
Anti-HIV Agents - pharmacology
Anti-HIV Agents - therapeutic use
Droplet digital PCR
Dual-regimen
Emtricitabine - therapeutic use
HIV Infections - drug therapy
HIV reservoir
Humans
Integrases
Residual viremia
Reverse Transcriptase Inhibitors - therapeutic use
RNA - therapeutic use
Single-tablet regimen
Tenofovir - therapeutic use
Total HIV-DNA
Viremia - drug therapy
title Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T07%3A59%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20HIV-DNA%20and%20residual%20viremia%20levels%20through%20week%2096%20in%20HIV-infected%20individuals%20who%20continue%20a%20two-drug%20or%20switch%20to%20a%20three-drug%20integrase%20strand%20transfer%20inhibitor-based%20regimen&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=Scutari,%20Rossana&rft.date=2023-05&rft.volume=61&rft.issue=5&rft.spage=106771&rft.epage=106771&rft.pages=106771-106771&rft.artnum=106771&rft.issn=0924-8579&rft.eissn=1872-7913&rft_id=info:doi/10.1016/j.ijantimicag.2023.106771&rft_dat=%3Cproquest_cross%3E2783496065%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2783496065&rft_id=info:pmid/36870403&rft_els_id=S0924857923000560&rfr_iscdi=true